U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07689721) titled 'ctDNA-Guided Intraventricular Therapy for CNS Malignancies' on July 01.
Brief Summary: This prospective, single-center study will evaluate whether cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) testing using the Belay Summit assay can improve the clinical management of patients with malignant gliomas or brain metastases from non-small cell lung cancer (NSCLC) or breast cancer who are suspected of having central nervous system (CNS) disease. Patients undergoing clinically indicated CSF evaluation will receive standard clinical testing, including CSF cytology and the Belay Summit ctDNA assay. Treatment decisions will remain at...